Neuroendocrine differentiation in prostate cancer: A mechanism of radioresistance and treatment failure

Frontiers in Oncology

Volumn 5, Issue APR, 2015, Pages

  Hu, Chang Deng ^a   Choo, Richard ^b   Huang, Jiaoti ^c  

^a PURDUE UNIVERSITY   (United States)

^b MAYO CLINIC   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

ATF2; Cancer stem cell; CREB; EMT; Neuroendocrine differentiation; Prostate cancer; Radiosensitization; Radiotherapy

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 2;

CANCER GROWTH; CANCER STEM CELL; CANCER SURVIVAL; DIFFERENTIATION; EPITHELIAL MESENCHYMAL TRANSITION; IONIZING RADIATION; NEUROENDOCRINE DIFFERENTIATION; NEUROENDOCRINE TUMOR; PROSTATE CANCER; PROTEIN EXPRESSION; RADIATION DOSE; RADIOSENSITIVITY; REVIEW; SENESCENCE; SIGNAL TRANSDUCTION; TREATMENT FAILURE;

EID: 84935090169     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2015.00090     Document Type: Review

References (108)

1. Siegel R, Desantis C, Virgo K, Stein K, Mariotto A, Smith T, et al. Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin (2012) 62(4):220-41. doi:10.3322/caac.21149
2. D'Amico AV. Risk-based management of prostate cancer. N Engl J Med (2011) 365(2):169-71. doi:10.1056/NEJMe1103829
3. D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA (1998) 280(11):969-74. doi:10.1001/jama.280.11.969
4. Boorjian SA, Karnes RJ, Viterbo R, Rangel LJ, Bergstralh EJ, Horwitz EM, et al. Long-term survival after radical prostatectomy versus external-beam radiotherapy for patients with high-risk prostate cancer. Cancer (2011) 117(13):2883-91. doi:10.1002/cncr.25900
5. Kuban DA, Thames HD, Levy LB, Horwitz EM, Kupelian PA, Martinez AA, et al. Long-term multi-institutional analysis of stage T1-T2 prostate cancer treated with radiotherapy in the PSA era. Int J Radiat Oncol Biol Phys (2003) 57(4):915-28. doi:10.1016/S0360-3016(03)00632-1
6. Zietman AL, DeSilvio ML, Slater JD, Rossi CJ Jr, Miller DW, Adams JA, et al. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. JAMA (2005) 294(10):1233-9. doi:10.1001/jama.294.10.1233
7. D'Amico AV, Chen MH, Renshaw AA, Loffredo B, Kantoff PW. Risk of prostate cancer recurrence in men treated with radiation alone or in conjunction with combined or less than combined androgen suppression therapy. J Clin Oncol (2008) 26(18):2979-83. doi:10.1200/JCO.2007.15.9699
8. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin (2010) 60(5):277-300. doi:10.3322/caac.20073
9. Harrington K, Jankowska P, Hingorani M. Molecular biology for the radiation oncologist: the 5Rs of radiobiology meet the hallmarks of cancer. Clin Oncol (R Coll Radiol) (2007) 19(8):561-71. doi:10.1016/j.clon.2007.04.009
10. Vashchenko N, Abrahamsson PA. Neuroendocrine differentiation in prostate cancer: implications for new treatment modalities. Eur Urol (2005) 47(2):147-55. doi:10.1016/j.eururo.2004.09.007
11. Bonkhoff H. Neuroendocrine differentiation in human prostate cancer. Morphogenesis, proliferation and androgen receptor status. Ann Oncol (2001) 12(Suppl 2):S141-4. doi:10.1023/A:1012454926267
12. di Sant'Agnese PA. Neuroendocrine differentiation in prostatic carcinoma: an update on recent developments. Ann Oncol (2001) 12(Suppl 2):S135-40. doi:10.1023/A:1012402909428
13. Mosca A, Berruti A, Russo L, Torta M, Dogliotti L. The neuroendocrine phenotype in prostate cancer: basic and clinical aspects. J Endocrinol Invest (2005) 28(11 Suppl):141-5.
14. Nelson EC, Cambio AJ, Yang JC, Ok JH, Lara PN Jr, Evans CP. Clinical implications of neuroendocrine differentiation in prostate cancer. Prostate Cancer Prostatic Dis (2007) 10(1):6-14. doi:10.1038/sj.pcan.4500922
15. Yuan TC, Veeramani S, Lin MF. Neuroendocrine-like prostate cancer cells: neuroendocrine transdifferentiation of prostate adenocarcinoma cells. Endocr Relat Cancer (2007) 14(3):531-47. doi:10.1677/ERC-07-0061
16. Cindolo L, Cantile M, Vacherot F, Terry S, de la Taille A. Neuroendocrine differentiation in prostate cancer: from lab to bedside. Urol Int (2007) 79(4):287-96. doi:10.1159/000109711
17. Conteduca V, Aieta M, Amadori D, De Giorgi U. Neuroendocrine differentiation in prostate cancer: current and emerging therapy strategies. Crit Rev Oncol Hematol (2014) 92(1):11-24. doi:10.1016/j.critrevonc.2014.05.008
18. Huang J, Wu C, di Sant'Agnese PA, Yao JL, Cheng L, Na Y. Function and molecular mechanisms of neuroendocrine cells in prostate cancer. Anal Quant Cytol Histol (2007) 29(3):128-38.
19. Daneshmand S, Quek ML, Pinski J. Neuroendocrine differentiation in prostate cancer. Cancer Ther (2005) 3:383-96.
20. Amorino GP, Parsons SJ. Neuroendocrine cells in prostate cancer. Crit Rev Eukaryot Gene Expr (2004) 14(4):287-300. doi:10.1615/CritRevEukarGeneExpr.v14.i4.40
21. Lilleby W, Paus E, Skovlund E, Fossa SD. Prognostic value of neuroendocrine serum markers and PSA in irradiated patients with pN0 localized prostate cancer. Prostate (2001) 46(2):126-33. doi:10.1002/1097-0045(20010201)46:2<126::AID-PROS1016>3.3.CO;2-Z
22. Krauss DJ, Hayek S, Amin M, Ye H, Kestin LL, Zadora S, et al. Prognostic significance of neuroendocrine differentiation in patients with Gleason score 8-10 prostate cancer treated with primary radiotherapy. Int J Radiat Oncol Biol Phys (2011) 81(3):e119-25. doi:10.1016/j.ijrobp.2010.12.064
23. Berruti A, Mosca A, Tucci M, Terrone C, Torta M, Tarabuzzi R, et al. Independent prognostic role of circulating chromogranin A in prostate cancer patients with hormone-refractory disease. Endocr Relat Cancer (2005) 12(1):109-17. doi:10.1677/erc.1.00876
24. Khan MO, Ather MH. Chromogranin A - serum marker for prostate cancer. J Pak Med Assoc (2011) 61(1):108-11.
25. Komiya A, Suzuki H, Imamoto T, Kamiya N, Nihei N, Naya Y, et al. Neuroendocrine differentiation in the progression of prostate cancer. Int J Urol (2009) 16(1):37-44. doi:10.1111/j.1442-2042.2008.02175.x
26. Quek ML, Daneshmand S, Rodrigo S, Cai J, Dorff TB, Groshen S, et al. Prognostic significance of neuroendocrine expression in lymph node-positive prostate cancer. Urology (2006) 67(6):1247-52. doi:10.1016/j.urology.2005.12.009
27. Taplin ME, George DJ, Halabi S, Sanford B, Febbo PG, Hennessy KT, et al. Prognostic significance of plasma chromogranin a levels in patients with hormone-refractory prostate cancer treated in cancer and leukemia group B 9480 study. Urology (2005) 66(2):386-91. doi:10.1016/j.urology.2005.03.040
28. Krauss DJ, Amin M, Stone B, Ye H, Hayek S, Cotant M, et al. Chromogranin A staining as a prognostic variable in newly diagnosed Gleason score 7-10 prostate cancer treated with definitive radiotherapy. Prostate (2014) 74(5):520-7. doi:10.1002/pros.22771
29. Xing N, Qian J, Bostwick D, Bergstralh E, Young CY. Neuroendocrine cells in human prostate over-express the anti-apoptosis protein survivin. Prostate (2001) 48(1):7-15. doi:10.1002/pros.1076
30. Gong J, Lee J, Akio H, Schlegel PN, Shen R. Attenuation of apoptosis by chromogranin A-induced Akt and survivin pathways in prostate cancer cells. Endocrinology (2007) 148(9):4489-99. doi:10.1210/en.2006-1748
31. Segal NH, Cohen RJ, Haffejee Z, Savage N. BCL-2 proto-oncogene expression in prostate cancer and its relationship to the prostatic neuroendocrine cell. Arch Pathol Lab Med (1994) 118(6):616-8.
32. Vanoverberghe K, Vanden Abeele F, Mariot P, Lepage G, Roudbaraki M, Bonnal JL, et al. Ca2+ homeostasis and apoptotic resistance of neuroendocrine-differentiated prostate cancer cells. Cell Death Differ (2004) 11(3):321-30. doi:10.1038/sj.cdd.4401375
33. Cox ME, Deeble PD, Lakhani S, Parsons SJ. Acquisition of neuroendocrine characteristics by prostate tumor cells is reversible: implications for prostate cancer progression. Cancer Res (1999) 59(15):3821-30.
34. Dayon A, Brizuela L, Martin C, Mazerolles C, Pirot N, Doumerc N, et al. Sphingosine kinase-1 is central to androgen-regulated prostate cancer growth and survival. PLoS One (2009) 4(11):e8048. doi:10.1371/journal.pone.0008048
35. Zelivianski S, Verni M, Moore C, Kondrikov D, Taylor R, Lin MF. Multipathways for transdifferentiation of human prostate cancer cells into neuroendocrine-like phenotype. Biochim Biophys Acta (2001) 1539(1-2):28-43. doi:10.1016/S0167-4889(01)00087-8
36. Deeble PD, Murphy DJ, Parsons SJ, Cox ME. Interleukin-6-and cyclic AMP-mediated signaling potentiates neuroendocrine differentiation of LNCaP prostate tumor cells. Mol Cell Biol (2001) 21(24):8471-82. doi:10.1128/MCB.21.24.8471-8482.2001
37. Merkle D, Hoffmann R. Roles of cAMP and cAMP-dependent protein kinase in the progression of prostate cancer: cross-talk with the androgen receptor. Cell Signal (2011) 23(3):507-15. doi:10.1016/j.cellsig.2010.08.017
38. Deeble PD, Cox ME, Frierson HF Jr, Sikes RA, Palmer JB, Davidson RJ, et al. Androgen-independent growth and tumorigenesis of prostate cancer cells are enhanced by the presence of PKA-differentiated neuroendocrine cells. Cancer Res (2007) 67(8):3663-72. doi:10.1158/0008-5472.CAN-06-2616
39. Bang YJ, Pirnia F, Fang WG, Kang WK, Sartor O, Whitesell L, et al. Terminal neuroendocrine differentiation of human prostate carcinoma cells in response to increased intracellular cyclic AMP. Proc Natl Acad Sci U S A (1994) 91(12):5330-4. doi:10.1073/pnas.91.12.5330
40. Park MH, Lee HS, Lee CS, You ST, Kim DJ, Park BH, et al. p21-Activated kinase 4 promotes prostate cancer progression through CREB. Oncogene (2013) 32(19):2475-82. doi:10.1038/onc.2012.255
41. Cox ME, Deeble PD, Bissonette EA, Parsons SJ. Activated 3',5'-cyclic AMP-dependent protein kinase is sufficient to induce neuroendocrine-like differentiation of the LNCaP prostate tumor cell line. J Biol Chem (2000) 275(18):13812-8. doi:10.1074/jbc.275.18.13812
42. Spiotto MT, Chung TD. STAT3 mediates IL-6-induced neuroendocrine differentiation in prostate cancer cells. Prostate (2000) 42(3):186-95. doi:10.1002/(SICI)1097-0045(20000215)42:3<186::AID-PROS4>3.0.CO;2-E
43. Lee SO, Chun JY, Nadiminty N, Lou W, Gao AC. Interleukin-6 undergoes transition from growth inhibitor associated with neuroendocrine differentiation to stimulator accompanied by androgen receptor activation during LNCaP prostate cancer cell progression. Prostate (2007) 67(7):764-73. doi:10.1002/pros.20553
44. Wang Q, Horiatis D, Pinski J. Inhibitory effect of IL-6-induced neuroendocrine cells on prostate cancer cell proliferation. Prostate (2004) 61(3):253-9. doi:10.1002/pros.20106
45. Wang Q, Horiatis D, Pinski J. Interleukin-6 inhibits the growth of prostate cancer xenografts in mice by the process of neuroendocrine differentiation. Int J Cancer (2004) 111(4):508-13. doi:10.1002/ijc.20286
46. Qiu Y, Robinson D, Pretlow TG, Kung HJ. Etk/Bmx, a tyrosine kinase with a pleckstrin-homology domain, is an effector of phosphatidylinositol 3'-kinase and is involved in interleukin 6-induced neuroendocrine differentiation of prostate cancer cells. Proc Natl Acad Sci U S A (1998) 95(7):3644-9. doi:10.1073/pnas.95.7.3644
47. Martin-Orozco RM, Almaraz-Pro C, Rodriguez-Ubreva FJ, Cortes MA, Ropero S, Colomer R, et al. EGF prevents the neuroendocrine differentiation of LNCaP cells induced by serum deprivation: the modulator role of PI3K/Akt. Neoplasia (2007) 9(8):614-24. doi:10.1593/neo.07337
48. Cortes MA, Cariaga-Martinez AE, Lobo MV, Martin Orozco RM, Motino O, Rodriguez-Ubreva FJ, et al. EGF promotes neuroendocrine-like differentiation of prostate cancer cells in the presence of LY294002 through increased ErbB2 expression independent of the phosphatidylinositol 3-kinase-AKT pathway. Carcinogenesis (2012) 33(6):1169-77. doi:10.1093/carcin/bgs139
49. Humez S, Monet M, Legrand G, Lepage G, Delcourt P, Prevarskaya N. Epidermal growth factor-induced neuroendocrine differentiation and apoptotic resistance of androgen-independent human prostate cancer cells. Endocr Relat Cancer (2006) 13(1):181-95. doi:10.1677/erc.1.01079
50. Sciarra A, Monti S, Gentile V, Mariotti G, Cardi A, Voria G, et al. Variation in chromogranin A serum levels during intermittent versus continuous androgen deprivation therapy for prostate adenocarcinoma. Prostate (2003) 55(3):168-79. doi:10.1002/pros.10222
51. Berruti A, Mosca A, Porpiglia F, Bollito E, Tucci M, Vana F, et al. Chromogranin A expression in patients with hormone naive prostate cancer predicts the development of hormone refractory disease. J Urol (2007) 178(3 Pt 1):838-43. doi:10.1016/j.juro.2007.05.018
52. Hirano D, Okada Y, Minei S, Takimoto Y, Nemoto N. Neuroendocrine differentiation in hormone refractory prostate cancer following androgen deprivation therapy. Eur Urol (2004) 45(5):586-92. doi:10.1016/j.eururo.2003.11.032
53. Sarkar D, Singh SK, Mandal AK, Agarwal MM, Mete UK, Kumar S, et al. Plasma chromogranin A: clinical implications in patients with castrate resistant prostate cancer receiving docetaxel chemotherapy. Cancer Biomark (2010) 8(2):81-7. doi:10.3233/CBM-2011-0198
54. Burgio SL, Conteduca V, Menna C, Carretta E, Rossi L, Bianchi E, et al. Chromogranin A predicts outcome in prostate cancer patients treated with abiraterone. Endocr Relat Cancer (2014) 21(3):487-93. doi:10.1530/ERC-14-0071
55. Conteduca V, Burgio SL, Menna C, Carretta E, Rossi L, Bianchi E, et al. Chromogranin A is a potential prognostic marker in prostate cancer patients treated with enzalutamide. Prostate (2014) 74(16):1691-6. doi:10.1002/pros.22890
56. Zhang XQ, Kondrikov D, Yuan TC, Lin FF, Hansen J, Lin MF. Receptor protein tyrosine phosphatase alpha signaling is involved in androgen depletion-induced neuroendocrine differentiation of androgen-sensitive LNCaP human prostate cancer cells. Oncogene (2003) 22(43):6704-16. doi:10.1038/sj.onc.1206764
57. Uysal-Onganer P, Kawano Y, Caro M, Walker MM, Diez S, Darrington RS, et al. Wnt-11 promotes neuroendocrine-like differentiation, survival and migration of prostate cancer cells. Mol Cancer (2010) 9:55. doi:10.1186/1476-4598-9-55
58. Yuan TC, Veeramani S, Lin FF, Kondrikou D, Zelivianski S, Igawa T, et al. Androgen deprivation induces human prostate epithelial neuroendocrine differentiation of androgen-sensitive LNCaP cells. Endocr Relat Cancer (2006) 13(1):151-67. doi:10.1677/erc.1.01043
59. Berenguer C, Boudouresque F, Dussert C, Daniel L, Muracciole X, Grino M, et al. Adrenomedullin, an autocrine/paracrine factor induced by androgen withdrawal, stimulates 'neuroendocrine phenotype' in LNCaP prostate tumor cells. Oncogene (2008) 27(4):506-18. doi:10.1038/sj.onc.1210656
60. Jongsma J, Oomen MH, Noordzij MA, Van Weerden WM, Martens GJ, van der Kwast TH, et al. Different profiles of neuroendocrine cell differentiation evolve in the PC-310 human prostate cancer model during long-term androgen deprivation. Prostate (2002) 50(4):203-15. doi:10.1002/pros.10049
61. Huss WJ, Gregory CW, Smith GJ. Neuroendocrine cell differentiation in the CWR22 human prostate cancer xenograft: association with tumor cell proliferation prior to recurrence. Prostate (2004) 60(2):91-7. doi:10.1002/pros.20032
62. Jongsma J, Oomen MH, Noordzij MA, Van Weerden WM, Martens GJ, van der Kwast TH, et al. Androgen deprivation of the PC-310 [correction of prohormone convertase-310] human prostate cancer model system induces neuroendocrine differentiation. Cancer Res (2000) 60(3):741-8.
63. Jongsma J, Oomen MH, Noordzij MA, Van Weerden WM, Martens GJ, van der Kwast TH, et al. Kinetics of neuroendocrine differentiation in an androgen-dependent human prostate xenograft model. Am J Pathol (1999) 154(2):543-51. doi:10.1016/S0002-9440(10)65300-X
64. Noordzij MA, van Weerden WM, de Ridder CM, van der Kwast TH, Schroder FH, van Steenbrugge GJ. Neuroendocrine differentiation in human prostatic tumor models. Am J Pathol (1996) 149(3):859-71.
65. Lin D, Wyatt AW, Xue H, Wang Y, Dong X, Haegert A, et al. High fidelity patient-derived xenografts for accelerating prostate cancer discovery and drug development. Cancer Res (2014) 74(4):1272-83. doi:10.1158/0008-5472.CAN-13-2921-T
66. Deng X, Liu H, Huang J, Cheng L, Keller ET, Parsons SJ, et al. Ionizing radiation induces prostate cancer neuroendocrine differentiation through interplay of CREB and ATF2: implications for disease progression. Cancer Res (2008) 68(23):9663-70. doi:10.1158/0008-5472.CAN-08-2229
67. Deng X, Elzey BD, Poulson JM, Morrison WB, Ko SC, Hahn NM, et al. Ionizing radiation induces neuroendocrine differentiation of prostate cancer cells in vitro, in vivo and in prostate cancer patients. Am J Cancer Res (2011) 1(7):834-44.
68. Palapattu GS, Wu C, Silvers CR, Martin HB, Williams K, Salamone L, et al. Selective expression of CD44, a putative prostate cancer stem cell marker, in neuroendocrine tumor cells of human prostate cancer. Prostate (2009) 69(7):787-98. doi:10.1002/pros.20928
69. Qin J, Liu X, Laffin B, Chen X, Choy G, Jeter CR, et al. The PSA(-/lo) prostate cancer cell population harbors self-renewing long-term tumor-propagating cells that resist castration. Cell Stem Cell (2012) 10(5):556-69. doi:10.1016/j.stem.2012.03.009
70. Kyjacova L, Hubackova S, Krejcikova K, Strauss R, Hanzlikova H, Dzijak R, et al. Radiotherapy-induced plasticity of prostate cancer mobilizes stem-like non-adherent, Erk signaling-dependent cells. Cell Death Differ (2014). doi:10.1038/cdd.2014.97
71. McKeithen D, Graham T, Chung LW, Odero-Marah V. Snail transcription factor regulates neuroendocrine differentiation in LNCaP prostate cancer cells. Prostate (2010) 70(9):982-92. doi:10.1002/pros.21132
72. Danza G, Di Serio C, Rosati F, Lonetto G, Sturli N, Kacer D, et al. Notch signaling modulates hypoxia-induced neuroendocrine differentiation of human prostate cancer cells. Mol Cancer Res (2012) 10(2):230-8. doi:10.1158/1541-7786.MCR-11-0296
73. Luo Y, Lan L, Jiang YG, Zhao JH, Li MC, Wei NB, et al. Epithelial-mesenchymal transition and migration of prostate cancer stem cells is driven by cancer-associated fibroblasts in an HIF-1alpha/beta-catenin-dependent pathway. Mol Cells (2013) 36(2):138-44. doi:10.1007/s10059-013-0096-8
74. Marhold M, Tomasich E, El-Gazzar A, Heller G, Spittler A, Horvat R, et al. HIF-1alpha regulates mTOR signaling and viability of prostate cancer stem cells. Mol Cancer Res (2014) 13(3):556-64. doi:10.1158/1541-7786.MCR-14-0153-T
75. Bhoumik A, Ronai Z. ATF2: a transcription factor that elicits oncogenic or tumor suppressor activities. Cell Cycle (2008) 7(15):2341-5. doi:10.4161/cc.6388
76. Lau E, Ronai ZA. ATF2-at the crossroad of nuclear and cytosolic functions. J Cell Sci (2012) 125(Pt 12):2815-24. doi:10.1242/jcs.095000
77. Liu H, Deng X, Shyu YJ, Li JJ, Taparowsky EJ, Hu CD. Mutual regulation of c-Jun and ATF2 by transcriptional activation and subcellular localization. EMBO J (2006) 25(5):1058-69. doi:10.1038/sj.emboj.7601183
78. Hsu CC, Hu CD. Critical role of N-terminal end-localized nuclear export signal in regulation of activating transcription factor 2 (ATF2) subcellular localization and transcriptional activity. J Biol Chem (2012) 287(11):8621-32. doi:10.1074/jbc.M111.294272
79. Canaff L, Bevan S, Wheeler DG, Mouland AJ, Rehfuss RP, White JH, et al. Analysis of molecular mechanisms controlling neuroendocrine cell specific transcription of the chromogranin A gene. Endocrinology (1998) 139(3):1184-96. doi:10.1210/en.139.3.1184
80. Shaywitz AJ, Greenberg ME. CREB: a stimulus-induced transcription factor activated by a diverse array of extracellular signals. Annu Rev Biochem (1999) 68:821-61. doi:10.1146/annurev.biochem.68.1.821
81. Suarez CD, Deng X, Hu CD. Targeting CREB inhibits radiation-induced neuroendocrine differentiation and increases radiation-induced cell death in prostate cancer cells. Am J Cancer Res (2014) 4(6):850-61.
82. Ahn S, Olive M, Aggarwal S, Krylov D, Ginty DD, Vinson C. A dominant-negative inhibitor of CREB reveals that it is a general mediator of stimulus-dependent transcription of c-fos. Mol Cell Biol (1998) 18(2):967-77.
83. Impey S, McCorkle SR, Cha-Molstad H, Dwyer JM, Yochum GS, Boss JM, et al. Defining the CREB regulon: a genome-wide analysis of transcription factor regulatory regions. Cell (2004) 119(7):1041-54. doi:10.1016/j.cell.2004.10.032
84. Xiao X, Li BX, Mitton B, Ikeda A, Sakamoto KM. Targeting CREB for cancer therapy: friend or foe. Curr Cancer Drug Targets (2010) 10(4):384-91. doi:10.2174/156800910791208535
85. Groner B, Weiss A. Targeting survivin in cancer: novel drug development approaches. BioDrugs (2014) 28(1):27-39. doi:10.1007/s40259-013-0058-x
86. Jin RJ, Wang Y, Masumori N, Ishii K, Tsukamoto T, Shappell SB, et al. NE-10 neuroendocrine cancer promotes the LNCaP xenograft growth in castrated mice. Cancer Res (2004) 64(15):5489-95. doi:10.1158/0008-5472.CAN-03-3117
87. Amorino GP, Deeble PD, Parsons SJ. Neurotensin stimulates mitogenesis of prostate cancer cells through a novel c-Src/Stat5b pathway. Oncogene (2007) 26(5):745-56. doi:10.1038/sj.onc.1209814
88. Ittmann M, Huang J, Radaelli E, Martin P, Signoretti S, Sullivan R, et al. Animal models of human prostate cancer: the consensus report of the New York meeting of the mouse models of human cancers consortium prostate pathology committee. Cancer Res (2013) 73(9):2718-36. doi:10.1158/0008-5472.CAN-12-4213
89. Greenberg NM, DeMayo F, Finegold MJ, Medina D, Tilley WD, Aspinall JO, et al. Prostate cancer in a transgenic mouse. Proc Natl Acad Sci U S A (1995) 92(8):3439-43. doi:10.1073/pnas.92.8.3439
90. Qi J, Nakayama K, Cardiff RD, Borowsky AD, Kaul K, Williams R, et al. Siah2-dependent concerted activity of HIF and FoxA2 regulates formation of neuroendocrine phenotype and neuroendocrine prostate tumors. Cancer Cell (2010) 18(1):23-38. doi:10.1016/j.ccr.2010.05.024
91. Mulholland DJ, Tran LM, Li Y, Cai H, Morim A, Wang S, et al. Cell autonomous role of PTEN in regulating castration-resistant prostate cancer growth. Cancer Cell (2011) 19(6):792-804. doi:10.1016/j.ccr.2011.05.006
92. Wang S, Gao J, Lei Q, Rozengurt N, Pritchard C, Jiao J, et al. Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. Cancer Cell (2003) 4(3):209-21. doi:10.1016/S1535-6108(03)00215-0
93. Angelsen A, Syversen U, Haugen OA, Stridsberg M, Mjolnerod OK, Waldum HL. Neuroendocrine differentiation in carcinomas of the prostate: do neuroendocrine serum markers reflect immunohistochemical findings? Prostate (1997) 30(1):1-6. doi:10.1002/(SICI)1097-0045(19970101)30:1<1::AID-PROS1>3.3.CO;2-B
94. Berruti A, Dogliotti L, Mosca A, Bellina M, Mari M, Torta M, et al. Circulating neuroendocrine markers in patients with prostate carcinoma. Cancer (2000) 88(11):2590-7. doi:10.1002/1097-0142(20000601)88:11<2590::AID-CNCR23>3.0.CO;2-D
95. Sasaki T, Komiya A, Suzuki H, Shimbo M, Ueda T, Akakura K, et al. Changes in chromogranin a serum levels during endocrine therapy in metastatic prostate cancer patients. Eur Urol (2005) 48(2):224-9. doi:10.1016/j.eururo.2005.03.017
96. D'Amico A. Radiation and hormonal therapy for locally advanced and clinically localized prostate cancer. Urology (2001) 58(2 Suppl 1):78-82. doi:10.1016/S0090-4295(01)01246-8
97. Pollack A, Kuban DA, Zagars GK. Impact of androgen deprivation therapy on survival in men treated with radiation for prostate cancer. Urology (2002) 60(3 Suppl 1):22-30. doi:10.1016/S0090-4295(02)01564-9
98. D'Amico AV. Radiation and hormonal therapy for locally advanced and clinically localized prostate cancer. Urology (2002) 60(3 Suppl 1):32-7. doi:10.1016/S0090-4295(02)01566-2
99. Lee WR. The role of androgen deprivation therapy combined with prostate brachytherapy. Urology (2002) 60(3 Suppl 1):39-44. doi:10.1016/S0090-4295(02)01568-6
100. Pollack A, Salem N, Ashoori F, Hachem P, Sangha M, von Eschenbach AC, et al. Lack of prostate cancer radiosensitization by androgen deprivation. Int J Radiat Oncol Biol Phys (2001) 51(4):1002-7. doi:10.1016/S0360-3016(01)01750-3
101. Pearlstein KA, Chen RC. Comparing dosimetric, morbidity, quality of life, and cancer control outcomes after 3D conformal, intensity-modulated, and proton radiation therapy for prostate cancer. Semin Radiat Oncol (2013) 23(3):182-90. doi:10.1016/j.semradonc.2013.01.004
102. Pugh TJ, Nguyen BN, Kanke JE, Johnson JL, Hoffman KE. Radiation therapy modalities in prostate cancer. J Natl Compr Canc Netw (2013) 11(4):414-21.
103. Mishra MV, Showalter TN. Pushing the limits of radiation therapy for prostate cancer: where do we go next? Semin Oncol (2013) 40(3):297-307. doi:10.1053/j.seminoncol.2013.04.005
104. Zaorsky NG, Harrison AS, Trabulsi EJ, Gomella LG, Showalter TN, Hurwitz MD, et al. Evolution of advanced technologies in prostate cancer radiotherapy. Nat Rev Urol (2013) 10(10):565-79. doi:10.1038/nrurol.2013.185
105. Koontz BF, Bossi A, Cozzarini C, Wiegel T, D'Amico A. A systematic review of hypofractionation for primary management of prostate cancer. Eur Urol (2014). doi:10.1016/j.eururo.2014.08.009
106. Morton GC. High-dose-rate brachytherapy boost for prostate cancer: rationale and technique. J Contemp Brachytherapy (2014) 6(3):323-30. doi:10.5114/jcb.2014.45759
107. Gray PJ, Efstathiou JA. Proton beam radiation therapy for prostate cancer-is the hype (and the cost) justified? Curr Urol Rep (2013) 14(3):199-208. doi:10.1007/s11934-013-0320-2
108. Efstathiou JA, Gray PJ, Zietman AL. Proton beam therapy and localised prostate cancer: current status and controversies. Br J Cancer (2013) 108(6):1225-30. doi:10.1038/bjc.2013.100